Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1992 5
1993 2
1994 3
1995 1
1996 2
1997 1
1998 1
2006 1
2007 1
2008 1
2010 2
2011 1
2012 5
2013 3
2014 6
2015 4
2016 5
2017 2
2018 6
2019 6
2020 4
2021 4
2022 6
2023 1
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
[Multiple sclerosis].
Frequin ST, Hommes OR. Frequin ST, et al. Ned Tijdschr Tandheelkd. 1992 Feb;99(2):46-8. Ned Tijdschr Tandheelkd. 1992. PMID: 11819990 Review. Dutch. No abstract available.
MRI pattern in asymptomatic natalizumab-associated PML.
Wattjes MP, Vennegoor A, Steenwijk MD, de Vos M, Killestein J, van Oosten BW, Mostert J, Siepman DA, Moll W, van Golde AE, Frequin ST, Richert ND, Barkhof F. Wattjes MP, et al. Among authors: frequin st. J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):793-8. doi: 10.1136/jnnp-2014-308630. Epub 2014 Sep 9. J Neurol Neurosurg Psychiatry. 2015. PMID: 25205744
Self-reported work productivity in people with multiple sclerosis and its association with mental and physical health.
van Egmond EEA, van Gorp DAM, Jongen PJ, van der Klink JJL, Reneman MF, Arnoldus EPJ, Beenakker EAC, van Eijk JJJ, Frequin STFM, Gerlach OHH, Hengstman GJD, Moll JWB, Verhagen WIM, Middelkoop HAM, Visser LH, van der Hiele K. van Egmond EEA, et al. Among authors: frequin stfm. Disabil Rehabil. 2022 Nov;44(23):7096-7105. doi: 10.1080/09638288.2021.1981468. Epub 2021 Oct 5. Disabil Rehabil. 2022. PMID: 34607481 Free article.
Subjective cognitive impairment is related to work status in people with multiple sclerosis.
van Wegen J, van Egmond EEA, Benedict RHB, Beenakker EAC, van Eijk JJJ, Frequin STFM, de Gans K, Gerlach OHH, van Gorp DAM, Hengstman GJD, Jongen PJ, van der Klink JJL, Reneman MF, Verhagen WIM, Middelkoop HAM, Visser LH, Hulst HE, van der Hiele K. van Wegen J, et al. Among authors: frequin stfm. IBRO Neurosci Rep. 2022 Nov 2;13:513-522. doi: 10.1016/j.ibneur.2022.10.016. eCollection 2022 Dec. IBRO Neurosci Rep. 2022. PMID: 36457855 Free PMC article.
69 results